 The three Illinois, 17 inhibitors, Sikukinumab, Ixacizumab, and Brodalumab are approved for treating moderate to severe plaque psoriasis, but only one study found treatment emergent antidrug antibodies, ADA, in 0.41% of patients during a 52-week treatment period. The study also found that two out of the four patients with ADA had neutralizing antibodies, but they were not associated with decreased efficacy. Only one study reported ADA against Ixacizumab, and 9% of patients developed titers to the drug after a loading dose followed by a maintenance dose. 19 out of 1,150, 1.7% developed high-titer ADA that impacted clinical outcomes. The variability in ADA development makes it difficult to draw a conclusion from the findings, but most trials did not develop ADA, and if they did, the majority of the time they were not neutralizing. Only Ixacizumab showed decreased efficacy in cases with neutralizing ADA, but no increased adverse events were reported. This article was offered by Logan W. Thomas, Erika B. Lee, and Jeshin J. Wu. We are article.tv, links in the description below.